A Phase II Neoadjuvant Clinical Trial of the Androgen Receptor Inhibitor Darolutamide in Early-Stage Androgen Receptor Positive (AR+) Triple-Negative Breast Cancer

Disease Sites:

Breast

Staging:

Phase II

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics, Surgery

Drugs:

Not Available

Principal Investigator(s):

Abramson, Vandana

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

09-09-2025

Trial Type:

Treatment

Protocol ID:

VICC-VCBRE23490

National Clinical Trial ID:

NCT07016399

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available